Alsmadi M, Jaradat M, Obaidat R, Alnaief M, Tayyem R, Idkaidek N
AAPS PharmSciTech. 2023; 24(6):172.
PMID: 37566183
DOI: 10.1208/s12249-023-02627-3.
Alqahtani F, Asiri A, Zamir A, Rasool M, Alali A, Alsanea S
Pharmaceutics. 2023; 15(4).
PMID: 37111735
PMC: 10140819.
DOI: 10.3390/pharmaceutics15041250.
Ballet V, Bohme G, Brohan E, Boukaiba R, Chambard J, Angouillant-Boniface O
Eur J Pharmacol. 2021; 915:174670.
PMID: 34863995
PMC: 9749463.
DOI: 10.1016/j.ejphar.2021.174670.
Ferreira P, Ferreira J, de Sousa R, Bezerra D, Militao G
J Oncol. 2021; 2021:3569349.
PMID: 34527050
PMC: 8437624.
DOI: 10.1155/2021/3569349.
Das S, Ramachandran A, Birangal S, Akbar S, Ahmed B, Joseph A
Med Drug Discov. 2021; 10:100085.
PMID: 33846702
PMC: 8026171.
DOI: 10.1016/j.medidd.2021.100085.
Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.
Zhang M, Yao X, Hou Z, Guo X, Tu S, Lei Z
Front Pharmacol. 2021; 11:585021.
PMID: 33643034
PMC: 7907647.
DOI: 10.3389/fphar.2020.585021.
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Themans P, Belkhir L, Dauby N, Yombi J, De Greef J, Delongie K
Eur J Drug Metab Pharmacokinet. 2020; 45(6):703-713.
PMID: 32968954
PMC: 7511144.
DOI: 10.1007/s13318-020-00648-y.
Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?.
Zhan X, Dowell S, Shen Y, Lee D
Heliyon. 2020; 6(9):e04900.
PMID: 32935064
PMC: 7480339.
DOI: 10.1016/j.heliyon.2020.e04900.
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.
Morrisette T, Lodise T, Scheetz M, Goswami S, Pogue J, Rybak M
Infect Dis Ther. 2020; 9(3):561-572.
PMID: 32740858
PMC: 7395206.
DOI: 10.1007/s40121-020-00325-2.
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Nicol M, Joshi A, Rizk M, Sabato P, Savic R, Wesche D
Clin Pharmacol Ther. 2020; 108(6):1135-1149.
PMID: 32687630
PMC: 7404755.
DOI: 10.1002/cpt.1993.
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?.
Machiels J, Bleeker-Rovers C, Ter Heine R, Rahamat-Langendoen J, de Mast Q, Ten Oever J
Int J Antimicrob Agents. 2020; 56(1):106056.
PMID: 32674929
PMC: 7357524.
DOI: 10.1016/j.ijantimicag.2020.106056.
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Maharaj A, Wu H, Hornik C, Balevic S, Hornik C, Smith P
JAMA Pediatr. 2020; 174(10):e202422.
PMID: 32501511
PMC: 7275264.
DOI: 10.1001/jamapediatrics.2020.2422.
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
Kastritis E, Wechalekar A, Schonland S, Sanchorawala V, Merlini G, Palladini G
Br J Haematol. 2020; 190(3):346-357.
PMID: 32480420
PMC: 7300844.
DOI: 10.1111/bjh.16898.
Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
Carlsson H, Hjorton K, Abujrais S, Ronnblom L, Akerfeldt T, Kultima K
Arthritis Res Ther. 2020; 22(1):125.
PMID: 32475347
PMC: 7261520.
DOI: 10.1186/s13075-020-02211-1.
Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
Al-Kofahi M, Jacobson P, Boulware D, Matas A, Kandaswamy R, Jaber M
Clin Pharmacol Ther. 2020; 108(4):766-769.
PMID: 32344449
PMC: 7267462.
DOI: 10.1002/cpt.1874.
Clearing the complexity: immune complexes and their treatment in lupus nephritis.
Toong C, Adelstein S, Phan T
Int J Nephrol Renovasc Dis. 2011; 4:17-28.
PMID: 21694945
PMC: 3108794.
DOI: 10.2147/IJNRD.S10233.
Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.
Brocks D, Mehvar R
Clin Pharmacokinet. 2003; 42(15):1359-82.
PMID: 14674788
DOI: 10.2165/00003088-200342150-00004.
Combination therapy for autoimmune diseases: the rheumatoid arthritis model.
Fathy N, Furst D
Springer Semin Immunopathol. 2001; 23(1-2):5-26.
PMID: 11455861
DOI: 10.1007/s002810100063.
Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.
Emami J, Pasutto F, Jamali F
Pharm Res. 1998; 15(6):897-903.
PMID: 9647356
DOI: 10.1023/a:1011928732588.
Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.
Ducharme J, Farinotti R
Clin Pharmacokinet. 1996; 31(4):257-74.
PMID: 8896943
DOI: 10.2165/00003088-199631040-00003.